MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on October 12, 2018, 08:29:18 am

Title: (ECTRIMS2018) Rituximab for MS doesn't increase cancer risk compared to Gilenya, Tysabri
Post by: agate on October 12, 2018, 08:29:18 am

Presented at the 2018 ECTRIMS conference in Berlin (October 10-12)--"Cancer risk among Swedish multiple sclerosis patients:  A nationwide cohort study comparing rituximab, fingolimod, and natalizumab":

http://www.professionalabstracts.com/ectrims2018/iplanner/#/presentation/293


Note: In the abstract, IR = Incidence Ratio



Title: Re: (ECTRIMS2018) Rituximab for MS doesn't increase cancer risk compared to Gilenya, Tysabri
Post by: agate on October 12, 2018, 08:34:59 am
An article about these findings in Multiple Sclerosis News Today (October 12, 2018)--"Rituximab cancer risk in MS compared to Gilenya, Tysabri":


https://multiplesclerosisnewstoday.com/2018/10/11/ectrims2018-rituximab-cancer-risk-ms-compared-gilenya-tysabri/